Friday, Jan 7, 1994
South San Francisco, Calif. -- January 7, 1994 --Genentech, Inc. announced today the commercial availability of Pulmozyme® (dornase alfa) recombinant human DNase, including a new comprehensive patient assistance program. Pulmozyme was licensed by the U.S. Food and Drug Administration (FDA) on; December 30 for the treatment of cystic fibrosis (CF).
Genentech has manufactured ample product supply to meet expected demand. Manufacturer's price of Pulmozyme is $27 per 2.5 mg ampule, the recommended daily dose, making the annualized cost of Pulmozyme $9,855. Pulmozyme is expected to be covered by private and government insurance plans.
Genentech has established the Pulmozyme Patient Pledge program so that CF patients in the United States who need Pulmozyme can obtain it, and to assure the CF community that Genentech's CF research will continue toward a cure.
Patients and their families in the United States are eligible to receive assistance in obtaining Pulmozyme if they are uninsured or underinsured and meet the income guidelines of the program. Genentech has also set up a toll free help line offering counseling and assistance to those who have questions about insurance coverage and reimbursement programs for Pulmozyme.
"As has always been the case with our products, no one in the United States who needs a Genentech medication will go without it due to inability to pay," said G. Kirk Raab, Genentech's president and chief executive officer. ''We believe the Pulmozyme Patient Pledge may be the most comprehensive patient assistance program ever introduced."
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.
# # #